Infection by P. aeruginosa is a challenge in therapeutic management. These bacteria can adapt to a hostile environment, resist the immune system, and block the action of broad-spectrum antibiotics such as thirdgeneration cephalosporin, carbapenems, and others . For that reason, the World Health Organization has classified P. aeruginosa with a critical priority for the development of new drugs .